Background
==========

The Canadian population is rapidly aging, with patients aged 85 + − the "oldest old" -- now representing one of the fastest growing age segments in the country \[[@B1]\]. Compared to their 65-to-74-year-old counterparts, these patients have more chronic health conditions \[[@B2]\], use more health services \[[@B3]\] and have seen a dramatic rise in medication prescriptions \[[@B4]\]. Increased consumption of health services and polypharmacy are trends reflected in the concept of "multimorbidity", which despite conflicting definitions is unequivocally more prevalent in patients aged 85+ than in any other age segment \[[@B5]-[@B7]\].

Much of the health care burden for this patient group falls on primary care providers \[[@B8]\]. As these providers seek to provide patient-centered and evidence-based care for this population, a major challenge lies in the lack of data describing even basic clinical characteristics of these patients as a group. Therefore, the primary objective of the present study is to determine the most prevalent health conditions and prescription medications among patients aged 85+ in an academic family practice setting. We will also describe the clinical complexity of these patients by using the "complexity score" \[[@B9]\] -- a clinical tool to measure the extent of multimorbidity in the elderly. Our data reveals trends which give rise to reflections on how clinical care of the oldest old patients can be improved.

Methods
=======

Ethics statement
----------------

Ethics approval was obtained prior to this study from the Sunnybrook Health Sciences Centre Research Ethics Office. This office specifically waived the requirement for written consent by the patients whose charts were reviewed.

Study design
------------

We conducted a retrospective chart review for all patients aged 85+ in the Family Practice Unit (FPU) at Sunnybrook Health Sciences Centre in Toronto, Canada.

Setting and study population
----------------------------

The Sunnybrook FPU is an academic primary care practice fully-affiliated with the University of Toronto. The clinic has 13 staff family physicians that belong to an FPU team which also comprises medical trainees, nurses, social workers, dietitians and diabetes educators. The FPU provides care to approximately 8,500 patients, with a focus on older patients with complex chronic disease. All patients who were 85 years of age or older as of January 1, 2011 and had complete medical records (current chronic health conditions and prescribed medications) were included in this study (N = 564; 209 males and 355 females).

Data collection
---------------

The electronic medical record of each eligible patient was reviewed and data was extracted from their Cumulative Patient Profile (CPP). The CPP is a section included in all Canadian electronic medical record systems \[[@B10]\] which allows family physicians to upkeep a patient's information in a compact fashion, including his or her current chronic conditions and medications. However, the information is not standardized. We used an automated script to abstract each patient's current chronic conditions and medication lists (CT) and manually reviewed the data for consistency and duplications (KC). Past medical history that was chronic in nature (e.g. hypertension, osteoarthritis) was counted as a current chronic condition.

Analysis
--------

Patients were grouped by sex and by 5-year age intervals (i.e. 85--89, 90--94, 95+) as determined by their age on January 1, 2011. Descriptive statistics for chronic illnesses and medications were calculated by sex and age group. For each patient, the "complexity score" was calculated by summing the number of long-term medications and the number of current chronic conditions. For example, a patient with five chronic conditions and three medications would be assigned a "complexity score" of eight. The "complexity score" is a measure that has been shown to have strong positive association with hospitalizations, emergency room visits, and family physician visits \[[@B9]\]. Patients were categorized by their complexity score into sextiles (i.e. 0--5, 6--10, 11--15, 16--20, 21--25, \>25), and the distribution was studied against age and sex.

Results
=======

Table [1](#T1){ref-type="table"} shows the demographics of the study population by age group and sex. Overall, there were more females (63%) than males (37%). This difference in the distribution of sex widened with increasing age. The total number of patients in this study comprised 6.4% of the 8767 total patients in the family practice.

###### 

Demographic profile of family practice patients aged 85+ at Sunnybrook Health Sciences Centre

            **85-89 yrs**   **90-94 yrs**   **95+ yrs**   **Total**
  --------- --------------- --------------- ------------- -----------
  **Sex**                                                  
  Female    219 (61)        113 (65)        23 (72)       355 (63)
  Male      140 (39)        60 (35)         9 (28)        209 (37)
  Total     359 (100)       173 (100)       32 (100)      564 (100)

Values are numbers (percentages) of patients.

Table [2](#T2){ref-type="table"} presents data on the 10 most common medical conditions in our study sample overall and by sex. Overall, patients in our study sample experienced 6.4 chronic medical conditions (data not shown). Four of the 10 most common diseases were cardiovascular risk factors (hypertension, dyslipidemia, atrial fibrillation, type 2 diabetes) with hypertension the most common, prevalent in approximately 65% of the study population. Both males and females shared these 4 conditions in their top 10 list, along with non-cardiovascular conditions such as osteoarthritis and hearing loss. In our sample, osteoporosis, hypothyroidism, and gastro-esophageal reflux disease (GERD) were more common in females. Among males, coronary artery disease (16.3%) was more prevalent.

###### 

Top 10 most common chronic conditions in patients aged 85+ by sex

       **Males**                     **Females**   **Overall**                                        
  ---- ----------------------------- ------------- --------------------- ------ --------------------- ------
  1    Hypertension                  61.7          Hypertension          66.8   Hypertension          64.9
  2    Benign prostate hypertrophy   28.7          Osteoporosis          49.6   Osteoarthritis        37.1
  3    Dyslipidemia                  28.2          Osteoarthritis        42.5   Osteoporosis          35.8
  4    Osteoarthritis                27.8          Dyslipidemia          23.4   Dyslipidemia          25.2
  5    Atrial fibrillation           27.3          Hypothyroidism        21.7   Atrial fibrillation   22.7
  6    Type 2 diabetes               22.0          Atrial fibrillation   20.0   Hypothyroidism        17.7
  7    Chronic renal failure         18.2          Osteopenia            17.5   Type 2 diabetes       17.2
  8    Hearing loss                  16.8          Type 2 diabetes       14.4   Hearing loss          15.1
  9    Coronary artery disease       16.3          GERD                  14.4   Osteopenia            13.5
  10   Glaucoma                      14.4          Hearing loss          14.1   Glaucoma              13.3

Table [3](#T3){ref-type="table"} presents the top 10 most common diseases by age group. Across age groups it is apparent that the prevalence of hypertension, osteoarthritis, and osteoporosis increased with age. Conversely, dyslipidemia, diabetes, and coronary artery disease decreased in prevalence with advancing age and were not among the 10 most common conditions in the highest age bracket.

###### 

Top 10 most common chronic conditions by age group

       **85-89 yrs**               **90-94 yrs**   **95+ yrs**                                         
  ---- --------------------------- --------------- --------------------- ------ ---------------------- ------
  1    Hypertension                63.2            Hypertension          67.1   Hypertension           71.9
  2    Osteoarthritis              35.4            Osteoarthritis        38.7   Osteoporosis           65.6
  3    Osteoporosis                32.0            Osteoporosis          38.2   Osteoarthritis         46.9
  4    Dyslipidemia                27.6            Hypothyroidism        24.3   Atrial fibrillation    31.3
  5    Atrial fibrillation         23.1            Dyslipidemia          22.5   GERD                   25.0
  6    Type 2 diabetes             18.9            Atrial fibrillation   20.2   Dementia (all types)   21.9
  7    Hypothyroidism              15.0            Hearing loss          19.1   Hearing loss           21.9
  8    Osteopenia                  13.7            Glaucoma              16.2   Hiatus hernia          18.8
  9    Degenerative disc disease   13.4            Type 2 diabetes       15.6   Depression             15.6
  10   Coronary artery disease     12.5            Osteopenia            13.9   Anemia                 12.5

Tables [4](#T4){ref-type="table"} and [5](#T5){ref-type="table"} present, respectively, the top 10 most common prescription medications and medication classes for each gender. Patients in our study were taking an average of 6.8 medications (data not shown). The range was 0 to 18 and the interquartile range was 5 to 9. Only 3 of the top 10 medication classes overall were meant for symptom relief, and these have been bolded in Table [5](#T5){ref-type="table"}. The remaining 7 classes were prescribed for risk factor modification, including 4 for cardiovascular disease alone. Overall, 88.7% of patients were taking some type of cardiovascular medication. 207 out of the 337 patients (61.4%) who had been prescribed either aspirin, a statin, or both medications did not have a diagnosis of either coronary artery disease or Type 2 diabetes charted in their CPP (data not shown). There were no medications for glycemic control in the top 10 list for any gender or age group.

###### 

Top 10 most common prescription medications in patients aged 85+ by sex

       **Males**             **Females**   **Overall**                                        
  ---- --------------------- ------------- --------------------- ------ --------------------- ------
  1    Atorvastatin          40.7          ASA (mini)            31.8   Atorvastatin          32.8
  2    ASA (mini)            34.0          Atorvastatin          28.2   ASA (mini)            32.6
  3    Ramipril              34.0          Hydrochlorothiazide   28.2   Hydrochlorothiazide   28.2
  4    Hydrochlorothiazide   28.2          Levothyroxine         26.8   Ramipril              25.7
  5    Metoprolol            26.3          Vitamin D             26.2   Amlodipine            23.8
  6    Warfarin              24.9          Amlodipine            25.4   Vitamin D             23.4
  7    Docusate              23.4          Alendronate           23.7   Levothyroxine         23.2
  8    Amlodipine            21.1          Ramipril              20.9   Warfarin              20.7
  9    Nitroglycerin spray   19.6          Acetaminophen         20.9   Docusate              20.6
  10   Vitamin D             18.7          Calcium               20.9   Metoprolol            19.0

###### 

Top 10 most common prescription medication classes in patients aged 85+ by sex

       **Males**                                                       **Females**   **Overall**                                                                                                                                
  ---- --------------------------------------------------------------- ------------- --------------------------------------------------------------- ---------- --------------------------------------------------------------- ----------
  1    Statins                                                         59.8          **Analgesics, non-opioid**                                      **50.4**   **Analgesics, non-opioid**                                      **50.2**
  2    **Analgesics, non-opioid**                                      **49.8**      Bisphosphonates                                                 47.3       Statins                                                         47.9
  3    Beta-blockers                                                   42.6          Statins                                                         40.8       Beta-blockers                                                   36.7
  4    Ace-inhibitors                                                  42.1          Calcium (alone or in combination with Vitamin D)                36.6       Bisphosphonates                                                 34.4
  5    Anti-thrombotic agents                                          35.9          CCBs                                                            35.5       CCBs                                                            34.0
  6    **PPIs**                                                        **35.4**      Beta-blockers                                                   33.2       **PPIs**                                                        **33.3**
  7    **BPH drugs**                                                   **35.4**      Thiazide diuretics (alone or in combination with other drugs)   32.7       Ace-inhibitors                                                  33.3
  8    CCBs                                                            31.6          **PPIs**                                                        **32.1**   Thiazide diuretics (alone or in combination with other drugs)   31.4
  9    **Drugs for constipation**                                      **30.6**      **Drugs for constipation**                                      **30.4**   **Drugs for constipation**                                      **30.5**
  10   Thiazide diuretics (alone or in combination with other drugs)   29.2          Ace-inhibitors                                                  28.2       Calcium (alone or in combination with Vitamin D)                30.3

The bolded medications are for symptom relief. PPIs, proton pump inhibitors; BPH drugs, benign prostatic hypertrophy drugs; CCBs, calcium channel blockers.

Tables [6](#T6){ref-type="table"} and [7](#T7){ref-type="table"} present, respectively, the top 10 most common prescription medications and medication classes by age group. Across age groups, we found that the rate of statin use declined with advancing age and the use of acetaminophen rose. There was a decline in the number of different medications for cardiovascular risk factors (particularly hypertension) with increasing age.

###### 

Top 10 most common prescription medications by age group

       **85-89 yrs**         **90-94 yrs**   **95+ yrs**                                  
  ---- --------------------- --------------- --------------------- ------ --------------- ------
  1    Atorvastatin          37.3            Amlodipine            31.2   Amlodipine      31.3
  2    ASA (mini)            34.5            Hydrochlorothiazide   30.1   Acetaminophen   31.3
  3    Hydrochlorothiazide   28.4            ASA (mini)            29.5   ASA (mini)      28.1
  4    Ramipril              26.5            Levothyroxine         29.5   Docusate        28.1
  5    Vitamin D             25.4            Ramipril              27.2   Atorvastatin    25.0
  6    Warfarin              22.3            Atorvastatin          24.9   Vitamin D       25.0
  7    Levothyroxine         20.9            Docusate              24.3   Warfarin        25.0
  8    Amlodipine            19.5            Vitamin D             19.1   Metoprolol      25.0
  9    Metoprolol            19.2            Alendronate           17.9   Alendronate     21.9
  10   Calcium               18.9            Acetaminophen         17.3   Calcium         21.9

###### 

Top 10 most common prescription medication classes by age group

       **85-89 yrs**                                                   **90-94 yrs**   **95+ yrs**                                                                                                               
  ---- --------------------------------------------------------------- --------------- --------------------------------------------------------------- ------ -------------------------------------------------- ------
  1    Statins                                                         54.3            Analgesics, non-opioid                                          46.2   Analgesics, non-opioid                             53.1
  2    Analgesics, non-opioid                                          51.8            CCBs                                                            43.4   Beta-blockers                                      40.6
  3    Beta-blockers                                                   37.3            Drugs for constipation                                          38.7   Bisphosphonates                                    40.6
  4    Ace-inhibitors                                                  34.5            Bisphosphonates                                                 38.7   Drugs for constipation                             37.5
  5    PPIs                                                            34.0            Statins                                                         37.6   CCBs                                               37.5
  6    Thiazide diuretics (alone or in combination with other drugs)   32.6            Beta-blockers                                                   34.7   Calcium (alone or in combination with Vitamin D)   34.4
  7    Bisphosphonates                                                 31.8            Ace-inhibitors                                                  34.7   Statins                                            31.3
  8    Anti-thrombotic Agents                                          31.5            PPIs                                                            32.9   Analgesics, opioids                                31.3
  9    Calcium (alone or in combination with Vitamin D)                31.2            Thiazide diuretics (alone or in combination with other drugs)   31.2   PPIs                                               28.1
  10   CCBs                                                            29.2            Thyroid therapy (hormone replacement or antithyroid)            30.1   Angiotensin II-antagonists, plain                  28.1

The complexity scores followed a mildly skewed right normal distribution across age and sex categories. The mean and median complexity scores in our sample were 13.3 and 12.5, respectively. The range was 2 to 29. We did not observe any significant differences between categories. Approximately one-third of our sample (35%; n = 198) had a complexity score between 11--15.

Discussion
==========

This large study of community-dwelling seniors over the age of 85 demonstrates that this population is afflicted by a large number of common chronic diseases and takes a large number of medications. Hypertension, osteoarthritis, dyslipidemia, atrial fibrillation, type 2 diabetes and hearing loss are highly prevalent in both sexes. Other conditions show variance between genders, suggesting that patterns noted in younger age groups such as females with hypothyroidism \[[@B11]\] and males with coronary artery disease \[[@B12]\] persist into older age.

The study of disease prevalence between age brackets in our data set also reveals insights that are relevant to the clinical care of younger seniors. Specifically, there seems to be a survivor effect for conditions such as dyslipidemia, diabetes, and coronary artery disease in that the patients who survived the longest were the least likely to be afflicted by these conditions. Such information may be valuable in conversations with patients about clinical decisions such as the continuance of cancer screening into age ranges that are not addressed in clinical practice guidelines, as the usefulness of such preventive health manoeuvres is affected by the patient's expected remaining lifespan. These types of conversations are becoming increasingly common in Canada with the rapidly growing senior cohort and the establishment of cancer screening programmes.

Many of the medications prescribed to patients in this study were for risk modification. Of the top 10 most frequently prescribed medication classes overall, only 3 (non-opioid analgesics, proton pump inhibitors, and drugs for constipation) were aimed at symptom relief. A similar pattern has been documented at the population level \[[@B4]\].

The extent of this disproportion is made more conspicuous by the fact that in an era where scientific evidence is so often cited to justify medical practice, there is a total lack of evidence in this age group to support the efficacy of the risk-modifying medications that are being prescribed with such frequency.

Furthermore, well-intentioned efforts to extend the length of life through risk modification may ironically result in worsening the quality of life in complex elderly patients. Other authors \[[@B13]\] have written about how patients can become confused and their daily schedules overtaken by complicated medication regimens resulting from the implementation of multiple clinical practice guidelines which may even contradict each other. Quality of life also suffers when patients experience medication adverse effects, which are more likely in the setting of polypharmacy \[[@B14]\].

There are some encouraging trends in our data which illustrate practical responses to the concerns outlined above. Firstly, while there are no risk-modifying medications shown to have benefit in this old population, there are some which may cause harm. These should be used with great caution. For example, diabetes medications can cause hypoglycemic episodes in the elderly \[[@B15]\] and our data indicate that the physicians whose patients we studied did not prescribe these medications frequently.

Secondly, while there is no evidence directly in the oldest old for risk-modifying medications, there are trends in the data from younger age groups which can be used to inform thoughtful prescribing decisions for their older counterparts. For example, it has been observed that the time to benefit \[[@B16]\] for many of these medications is often measured in years, and thus it is rational to use them less often as patients age and have fewer expected years of life remaining. In our data set, this principle is reflected in the decreasing use of statin medications with increasing age and the infrequent use of anti-hyperglycemics.

There was no difference in complexity scores between age or sex categories, but the overall median score of 12.5 indicates a high level of complexity in this patient population. This translates into a more than 2-fold potential increase in hospitalization and emergency department admissions compared to patients with a complexity score between 0--5 \[[@B9]\]. Although the mean complexity score in this patient sample was high, the distribution of scores was wide (ranging from 2 to 29). This reflects the heterogeneous nature of even the oldest old population and serves as a useful reminder for the clinician that they must not be viewed through a "one size fits all" lens. The most complex patients take a large number of medications and are at high risk for drug interactions, and thus it is even more difficult to justify further complicating their regimen with additional unproven risk-modifying medications as discussed above. Conversely, there are patients over 85 years old who have low clinical complexity and excellent quality of life who wish to take these medications even while recognizing the lack of data derived from subjects their age, because there is a chance that they will benefit and live longer as a result. Such patient preferences should be respected. In fact, recent guidelines \[[@B17]\] have made explicit this very idea of a patient-centred approach to risk modification that accounts for a patient\'s clinical status.

The major strength of this study is the large number of patients 85 years of age and older who were included.

This study is subject to certain limitations. The sample of patients came from a single primary care unit in an academic health centre in Toronto, located in an educated and affluent neighborhood. Each of these traits may have an influence on the ability to generalize our results to other seniors over the age of 85. For example, the high rate of osteoporosis may be due to the fact that in an academic environment, great emphasis was placed upon adhering to screening guidelines. It has been shown elsewhere that poor socioeconomic status (SES) places one at higher risk for coronary artery disease \[[@B18]\], and thus the relatively low rate of CAD in our study may be partially explained by the clinic's location in a high SES neighborhood.

The study was also limited because its data was extracted exclusively from the CPP. Each patient\'s physician is responsible for the upkeep of this portion of the patient chart, and therefore variation in their charting habits could have influenced our results. For example, the disparity between the prevalence of osteoporosis in females and prescriptions of calcium and Vitamin D may be due to the fact that clinicians recommended that their patients buy these supplements over-the-counter, and did not record this in their medication list. It is also likely that we missed chronic conditions which were not entered in the CPP despite being documented in the body of patients' charts.

Conclusions and recommendations
===============================

As the aging Canadian population expands and their burden of health care falls largely on the shoulders of family physicians, it is becoming ever more important to understand the health characteristics and medication profiles of the oldest old. Our study demonstrates that 6.4% of the patients in a family practice are above 85 years old, and that the majority of documented chronic conditions in this population are related to both cardiovascular and bone health. The data also highlights the significant number of medications used on a daily basis by older adults. This information provides the basis for reflection on several issues relevant to the clinical care of the oldest old such as the necessity of risk-modifying medications, the prioritization of quality versus quantity of life, and the importance of recognizing heterogeneity in this population.
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